Enzyme Replacement Therapy Market

Report Description
Table of Contents

Report Description

The global enzyme replacement therapy market size is estimated to be USD 7,825.9 million in 2020 and is expected to witness a CAGR of 5.81% during the forecast period. Rising accessibility of enzyme replacement treatment coupled with growing research & development activities are key drivers for the growth of the global enzyme replacement therapy market. Additionally, the increase in awareness, liberalisation of regulatory protocols, government support, and intensifying competition among market players are some of the other drivers propelling the market growth. However, the sluggish enzyme therapy adoption due to existing treatment solution is expected to restrain the global market growth.

Global Enzyme Replacement Therapy Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Enzyme Type

Based on enzyme type, the market is divided into taliglucerase, imiglucerase, agalsidase beta, laronidase, velaglucerase alfa, galsulfase, alglucosidase alfa, pancreatic enzymes, pegademase, idursulfase, and others. In 2020, the velaglucerase alfa and imiglucerase segment accounted for the dominant revenue share with lucrative CAGR during the forecast period. This is attributed to the high prevalence of Gauchers’ disease worldwide. Agalsidase beta segment projected to grow at a profitable CAGR during the forecast period. This is attributed to rising research and development and growing Fabry’s disease cases.

By Application

Based on application, the market is categorized into SCID, Fabry disease, Gaucher disease, Pompe disease, MPS, and others. The Gaucher disease segment accounted for significant revenue in 2020 and is projected to maintain its dominance over the forecast period. The occurrence of this disease due to recessive mutation is a key factor that drives the segment growth. The SCID and MPS segments are anticipated to grow at a lucrative CAGR during the forecast period owing rising awareness among biopharmaceutical companies.

By Route of Administration

Based on technology, the market is categorized into parenteral and oral. In 2020, the Parenteral route segment accounted for the maximum revenue share due to its quick ability to for mediating quick drug delivery and absorption. This segment is anticipated to grow at the fastest CAGR during the forecast period, due to the high large product and service offering in this segment.

By End-Use

Based on end-use, the market is categorized into infusion centres, hospitals, and others. The hospitals segment accounted for the highest revenue in 2020 and is projected to maintain its dominance over the forecast period. The patient admission in hospitals is a key factor that drives the segment growth.

Regional Insights

In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of leading biopharmaceutical companies, advanced healthcare infrastructure, and high investments in R&D in this region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the rising cases of rare diseases, government aid in healthcare sector, escalating demand for advanced medication and treatment, and growing focus of CROs & biopharmaceutical companies in this region.

Competitor Insights

Some of the key players in the enzyme replacement therapy market are Protalix BioTherapeutics (Israel); Recordati (Italy); Johnson & Johnson (U.S.); Horizon Therapeutics plc (Ireland); AbbVie Inc. (U.S.); Alexion Pharmaceuticals Inc. (U.S.); BioMarin Pharmaceutical Inc. (U.S.); Sanofi S.A. (France); and Takeda Pharmaceutical Company Limited (Japan). The leading players operating in the enzyme replacement therapy industry are adopting various strategies including R&D investments, adaption of advanced techniques, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The enzyme replacement therapy market report is categorized into the following segments and subsegments: